A Phase 1 interventional study of Meloxicam gel and Meloxicam tablet in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study to gain information on the percutaneous absorption of meloxicam after administration of a topical gel over 7 days.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For female subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Meloxicam gel
Drug: Meloxicam tablet
Analysis of plasma concentration-time course after topical dose
Time frame: up to 264 hours after first topical administration
Determination of the ratio AUCss topical/AUC0-∞ oral
Time frame: up to 96 hours after oral administration
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: up to 96 hours after oral administration
Time from dosing to the maximum concentration of the analyte in plasma (Tmax)
Time frame: up to 96 hours after oral administration
Total area under the plasma drug concentration time curve (AUC) from time of administration to the time of the last quantifiable drug concentration (AUC0-t)
Time frame: up to 96 hours after oral administration
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: up to 96 hours after oral administration
Terminal half-life of the analyte in plasma (t½)
Time frame: up to 96 hours after oral administration
Apparent terminal elimination rate constant
Time frame: up to 96 hours after oral administration
Apparent clearance of the analyte in plasma following extravascular administration (CL/F)
Time frame: up to 96 hours after oral administration
Apparent volume of distribution of the analyte during the terminal phase (Vz/F)
Time frame: up to 96 hours after oral administration
Mean residence time (MRTtot)
Time frame: up to 96 hours after oral administration
Excretion of metabolites in urine
Time frame: 0-24 hours after oral administration
Predose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss)
Time frame: up to 264 hours after first topical administration
Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)
Time frame: up to 264 hours after first topical administration
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Time frame: up to 264 hours after first topical administration
Total area under the plasma drug concentration time curve (AUC) during a steady state interval (AUCss)
Time frame: up to 264 hours after first topical administration
Terminal half-life of the analyte in plasma (t½)
Time frame: up to 264 hours after first topical administration
Apparent terminal elimination rate constant
Time frame: up to 264 hours after first topical administration
Occurence of adverse events
Time frame: up to 24 days
Assessment of local and systemic tolerability
Time frame: up to 24 days
No study locations are listed for this record.
The record gives a start of Sep 1998 and a primary completion of Nov 1998. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Meloxicam